Some were known cancer genes, including CDKN2A, KEAP1, MYCN, PLK4, SETD2, TP53. It is possible that any of these singleton genetic changes contributed to resistance to rapalog therapy in an individual patient. This evidence concerns the gene CDKN2A and cancer.